Literature DB >> 18305030

Enumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infection.

Christopher C Kemball1, Stephanie Harkins, J Lindsay Whitton.   

Abstract

Previous studies have suggested that coxsackievirus B (CVB) activates CD8(+) T cells in vivo, but the extent of this activation and the antigen specificity of the CD8(+) T cells remain uncertain. Furthermore, CVB-induced CD4(+) T-cell responses have not been carefully investigated. Herein, we evaluate CD8(+) and CD4(+) T-cell responses both in a secondary lymphoid organ (spleen) and in peripheral tissues (heart and pancreas), using a recombinant CVB3 (rCVB3.6) that encodes well-characterized CD8(+) and CD4(+) T-cell epitopes. Despite reaching high levels in vivo, rCVB3.6 failed to trigger a marked expansion of CD8(+) or CD4(+) T cells, and T-cell activation was surprisingly limited. Furthermore, epitope-specific effector functions could not be detected using highly sensitive in vivo and ex vivo assays. Moreover, major histocompatibility complex (MHC) class I tetramer analysis indicated that our inability to detect CVB3-specific CD8(+) T-cell responses could not be explained by the cells being dysfunctional. In contrast to naïve T cells, epitope-specific memory CD8(+) and CD4(+) T cells proliferated markedly, indicating that both of the rCVB3.6-encoded epitopes were presented by their respective MHC molecules in vivo. These data are consistent with the observation that several CVB3 proteins can limit the presentation of viral epitopes on the surface of infected cells and suggest that the level of MHC/peptide complex is sufficient to trigger memory but not naïve T cells. Finally, our findings have implications for the biological significance of cross-priming, a process thought by some to be important for the induction of antiviral CD8(+) T-cell responses.

Entities:  

Mesh:

Year:  2008        PMID: 18305030      PMCID: PMC2293035          DOI: 10.1128/JVI.02639-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Structure-function analysis of the coxsackievirus protein 3A: identification of residues important for dimerization, viral rna replication, and transport inhibition.

Authors:  Els Wessels; Richard A Notebaart; Daniël Duijsings; Kjerstin Lanke; Bart Vergeer; Willem J G Melchers; Frank J M van Kuppeveld
Journal:  J Biol Chem       Date:  2006-07-25       Impact factor: 5.157

2.  A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport.

Authors:  Els Wessels; Daniël Duijsings; Richard A Notebaart; Willem J G Melchers; Frank J M van Kuppeveld
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice.

Authors:  Sally A Huber; Arthur M Feldman; Danielle Sartini
Journal:  Circ Res       Date:  2006-10-12       Impact factor: 17.367

4.  Poliovirus protein 3A inhibits tumor necrosis factor (TNF)-induced apoptosis by eliminating the TNF receptor from the cell surface.

Authors:  N Neznanov; A Kondratova; K M Chumakov; B Angres; B Zhumabayeva; V I Agol; A V Gudkov
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Echovirus infection causes rapid loss-of-function and cell death in human dendritic cells.

Authors:  Matthijs Kramer; Barbara M Schulte; Liza W J Toonen; Mike A M de Bruijni; Jochem M D Galama; Gosse J Adema; Frank J M van Kuppeveld
Journal:  Cell Microbiol       Date:  2007-02-09       Impact factor: 3.715

6.  Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia.

Authors:  N T Hertel; F K Pedersen; C Heilmann
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

7.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Selection of an attenuated Coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen.

Authors:  N Van Houten; P E Bouchard; A Moraska; S A Huber
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.

Authors:  S Mandl; L J Sigal; K L Rock; R Andino
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 10.  Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy.

Authors:  M J Sole; P Liu
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

View more
  11 in total

Review 1.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

Review 2.  Induction and function of virus-specific CD4+ T cell responses.

Authors:  Jason K Whitmire
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

Review 3.  Type B coxsackieviruses and their interactions with the innate and adaptive immune systems.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

4.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

5.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

6.  Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy.

Authors:  Deanna A Hagge; Bernadette M Saunders; Gigi J Ebenezer; Nashone A Ray; Vilma T Marks; Warwick J Britton; James L Krahenbuhl; Linda B Adams
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

7.  AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.

Authors:  Liang Yin; Dafei Chai; Yan Yue; Chunsheng Dong; Sidong Xiong
Journal:  Front Cell Infect Microbiol       Date:  2017-06-08       Impact factor: 5.293

8.  PA28 modulates antigen processing and viral replication during coxsackievirus B3 infection.

Authors:  Dorota Respondek; Martin Voss; Ina Kühlewindt; Karin Klingel; Elke Krüger; Antje Beling
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

9.  ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.

Authors:  Hannah Louise Neumaier; Shelly Harel; Karin Klingel; Ziya Kaya; Arnd Heuser; Meike Kespohl; Antje Beling
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

10.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.